Best Stocks Under $10 Right Now Show: Overview Stocks Under $0.50 Stocks Under $1.00 Stocks Under $2.00 Stocks Under $5.00 Stocks Under $10.00 Stocks Under $20.00 Stocks Under $30.00 Stocks Under $50.00 Stocks On Sale Written by MarketBeat StaffAugust 1, 2022How Is a Company’s Share Price Calculated?Should Investors Buy Stocks Under $10?What Are the Rewards of Stocks Under $10?What Are the Risks of Buying Stocks Under $10?What Are the Best Stocks Under $10?A common mistake among novice investors is confusing an undervalued stock with a cheap stock. When a stock trades under $5 (often called penny stocks), it can be easy for an investor to understand why the stock carries such a low price. But when a stock trades below $10, a little more research is required. This is particularly true when the broader market is in a sell-off. Before attempting to buy stocks that are trading for less than 10 dollars, there are some important things to know. How Is a Company’s Share Price Calculated? If you’re an experienced investor this is just a basic review. But if you’re a relatively new investor this may help answer a lot of questions. To understand why buying stocks under $10 can come with an elevated risk you need to understand how a company’s stock price is calculated. There are two data points to look for. The first is a company’s market capitalization (or market cap). That is a rough estimation of how much a company is worth. The second number is the number of outstanding shares (also called shares outstanding – the meaning is the same). This is, as the name suggests, the number of common shares available to be bought. To calculate a company’s stock price, you divide the company’s current market capitalization by its number of outstanding shares. Here’s an example that keeps the math easy. A stock that is valued at $100 million and has 1 million outstanding shares has a share price of $100. But a stock that is valued at $100 million and has 100 million outstanding shares has a share price of $10. The important thing to take away from that example is a stock’s price does not necessarily reflect the market value of the company. Now here’s a real world example. On March 27, General Electric (NYSE:GE) had a market cap of $66.37 billion. The company had 8.74 billion outstanding shares. When you divide the market cap by the outstanding shares you get 7.59. 66.37/8.74 = 7.59 This means at that moment, one share of GE stock was valued at $7.59. Should Investors Buy Stocks Under $10? The simple answer is “Of course you should.” A common fallacy among even the most experienced investors is failing to understand the difference between a stock that is cheap and one that is undervalued. It’s an interesting aspect of human psychology. A stock that is trading at $200 could decline by 25% and investors will swoop in to buy it “on sale”. But if a $12 stock drops 20% it becomes untouchable. The problem with this approach is it assumes that a high price is good and a low price is bad. And in fairness, that can be true. Many stocks that trade under $10 do so because they present obvious and fundamentally problematic issues that are suppressing their growth. So if you’re an investor who is looking to buy stocks under $10 is be sure you’re ready, and able, to do some research. Simply throwing your hard-earned money at a stock because you’ve heard the mantra “buy low, sell high” is foolish. But the same can be said of investing in any stock. And if you’re reading this article, I hope you already understand that stocks over time can be an excellent and sound investment. Stock prices, no matter the price, can fluctuate wildly. But over time, investing in stocks has proven to be the most reliable path to reaching your financial goals. And the simple truth is that a stock that is trading under $10 can offer you the ability to make huge gains. But that is, if you know what to look for. Fortunately, in this article, we’ve done a lot of that research for you. But there is one caveat about investing in stocks under $10. This should only make up a small portion of the stock portion of your portfolio. The majority of your investment in equities (another name for stocks) should focus on solid, stable companies. And depending on your investment style, you should look for companies that pay a dividend. You should also not invest in stocks under $10 to replace money you have set aside in bonds or cash. This should be money that you are already investing in the market. What Are the Rewards of Stocks Under $10? The reward of buying stocks under $10 is the opportunity for growth. If you can buy 1000 shares of a stock that is trading at $8, you would only need the stock to increase in value by $8 to double your investment. If you were That, however, is easier said than done. And many investors have seen that $8,000 investment evaporate as they bought shares of a falling knife. Still, if investors can find the right stock, stocks under $10 are one of the best ways to capture a significant gain without a large investment. That brings up a second point. Stocks under $10 are more accessible for investors without a lot of money to put into the market. Robinhood and other trading apps are designed on this principle. If you only have a small amount of money to invest, you don’t have to put all your eggs in one basket. In practical terms, and investor with $10,000 to invest could buy over 150 shares a stock that is currently trading below $7 a share. This also makes stocks under $10 a great option for diversification. Not only can you look at different sectors, but you can also dabble in international stocks. What Are the Risks of Buying Stocks Under $10? Here are some of the most common risks of buying stocks under $10: Share dilution - Generally, the number of outstanding shares is driven by simple supply and demand. A company that issues a solid earnings report, or comes out with a new product, etc. will see their outstanding shares decline because there will be more buyers than sellers.In other words, the stock is harder to buy. If an investor wants to buy it, a seller will demand a higher price to let their shares go. And when there are more sellers than buyers, there will be a higher number of outstanding shares. In other words, sellers have to accept a lower price for the shares they purchased to entice a buyer to buy.However, when a company gets into financial trouble, it becomes difficult for them to get loans. When a company has limited free cash flow (FCF), they are seen as a credit risk. This simply means lenders believe there is a high probability that the company will default on the loan.When this happens, one strategy they may execute is to issue more shares. This almost always dilutes the value of the existing shares, which in turn drives the price down further. Increased competition - Young startup companies often have a first mover advantage. Because they are creating a new market, they have no competition and have no price pressure. However, as more competitors enter the market, a company may face pressure both on the price they charge and their profit margin. If the company is slow to adapt to the competition, their stock price may sink to extremely low levels. The company operates in a cyclical industry - A retailer may see their stock spike during the holiday season as investors anticipate greater revenue and profit. However, for the remainder of the year, the company may not be able to sustain that revenue. That’s another reason the stock may sink. The stock is low- to no-growth stock - If you look at the price history of a stock, it may just trade in a specific range. In that case, a stock under $10 may still be a worthwhile investment if it pays a nice dividend. What Are the Best Stocks Under $10? If you’ve followed this article and understand both the pros and cons of stocks under $10, let’s take a look at how you can put that information to work in the middle of one of the greatest stock sell-offs in history. On the one hand, there are a number of quality companies that have seen their share price reach uncomfortably low levels. But some of these stocks are in industries like hospitality that have been particularly affected by the coronavirus. And while these stocks are generally perceived to see increased, pent-up demand once the coronavirus threat recedes, it may be some time before this increased demand shows up in the stock price. Value investing opportunities do exist—if you're looking in the right places. Putting together a list of the best stocks under $10.00 requires investors to do their homework. At a price of under $10, these companies are not penny stocks. In fact many companies have a large market cap. But just because a stock is trading for a low price doesn’t make it a great value. One of the biggest assets an investor can have is time. If you’ve done your due diligence and believe in the overall financial health and direction of the company, buying stocks under $10 can be very profitable. If you have the time and patience to hold the stock through many economic cycles, here are some stocks to consider. Low Priced StocksOverviewStocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage. Top Headlines and OffersView All HeadlinesUber’s NVIDIA Deal and Buybacks Signal Major UpsideBy Jeffrey Neal Johnson | January 17, 2025View Uber’s NVIDIA Deal and Buybacks Signal Major UpsideBeyond Rigetti: Top 3 Quantum Computing Stock PicksBy Chris Markoch | January 21, 2025View Beyond Rigetti: Top 3 Quantum Computing Stock PicksStunning Trump Manhattan Project Now UnderwayFrom Banyan Hill Publishing(Ad)View Stunning Trump Manhattan Project Now UnderwayAI Demand Sparks Opportunities for These 3 Nuclear Energy LeadersBy Nathan Reiff | January 17, 2025View AI Demand Sparks Opportunities for These 3 Nuclear Energy LeadersTop ETFs That Beat the Market in 2024 and Could Do It AgainBy Nathan Reiff | January 18, 2025View Top ETFs That Beat the Market in 2024 and Could Do It AgainCerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?By Leo Miller | January 16, 2025View Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?Trump’s Sending THIS Crypto Higher on PurposeFrom Crypto 101 Media(Ad)View Trump’s Sending THIS Crypto Higher on Purpose3 Stocks to Gain From Donald Trump’s External Revenue ServiceBy Jea Yu | January 20, 2025View 3 Stocks to Gain From Donald Trump’s External Revenue ServiceEarn High Dividends With 2 Top REITs Set to Perform in 2025By Jeffrey Neal Johnson | January 19, 2025View Earn High Dividends With 2 Top REITs Set to Perform in 2025Top Growth Picks: 3 Low-Cost Stocks That Could Double in ValueBy Chris Markoch | January 17, 2025View Top Growth Picks: 3 Low-Cost Stocks That Could Double in ValueEnergy Sector Shines in 2025: 2 Stocks Leading the ChargeBy Ryan Hasson | January 17, 2025View Energy Sector Shines in 2025: 2 Stocks Leading the ChargeTreasury nominee calls for stronger Russia sanctions and Fed independence at confirmation panelBy The Associated Press | January 15, 2025View Treasury nominee calls for stronger Russia sanctions and Fed independence at confirmation panel #1 - GlencoreOTCMKTS:GLNCYStock Price: $9.18 (-$0.20)Market Cap: $56.00 billionAverage Trading Volume: 1.05 million sharesDividend Yield: 2.41%<Consensus Rating: Strong Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AGlencore plc engages in the production, refinement, processing, storage, transport, and marketing of metals and minerals, and energy products in the Americas, Europe, Asia, Africa, and Oceania. It operates through two segments: Marketing Activities and Industrial Activities. The company engages in production and marketing copper, cobalt, lead, nickel, zinc, chrome ore, ferrochrome, vanadium, aluminum, alumina, and iron ore; and coal, crude oil, refined products, and natural gas, as well as oil exploration/production and refining/distribution. It also operates marketing and distribution of physical commodities sourced from third party producers and company's production to industrial consumers, including the battery, electronic, construction, automotive, steel, energy, and oil industries. In addition, the company provides financing, logistics, and other services to producers and consumers of commodities. Glencore plc was founded in 1974 and is headquartered in Baar, Switzerland. Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. #2 - Green Thumb IndustriesOTCMKTS:GTBIFStock Price: $7.16 (-$0.26)P/E Ratio: 29.81Market Cap: $1.51 billionAverage Trading Volume: 414,886 sharesConsensus Rating: Strong Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $16.50 (130.6% Upside)Green Thumb Industries Inc. manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, capsules, tinctures, edibles, topicals, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RHYTHM brands. It distributes its products primarily to third-party retail customers and sells finished products directly to consumers in its own retail stores, as well as direct-to consumer delivery channel. Green Thumb Industries Inc. was founded in 2014 and is headquartered in Chicago, Illinois.#3 - Denison MinesNYSEAMERICAN:DNNStock Price: $2.04 (+$0.08)P/E Ratio: -204.00Market Cap: $1.83 billionAverage Trading Volume: 30.18 million sharesConsensus Rating: Strong Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.00 (47.1% Upside)Denison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. Its flagship project is the Wheeler River uranium project covering an area of approximately 300,000 hectares located in the Athabasca Basin region in northern Saskatchewan. The company was formerly known as International Uranium Corporation and changed its name to Denison Mines Corp. in December 2006. Denison Mines Corp. was incorporated in 1936 and is headquartered in Toronto, Canada.#4 - Mereo BioPharma GroupNASDAQ:MREOStock Price: $2.92 (-$0.07)Market Cap: $453.04 millionAverage Trading Volume: 1.48 million sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $7.83 (168.3% Upside)Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.#5 - OnKure TherapeuticsNASDAQ:OKURStock Price: $5.70 (-$0.20)P/E Ratio: -0.47Market Cap: $19.06 millionAverage Trading Volume: 131,172 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $36.00 (531.6% Upside)OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.#6 - Hudbay MineralsNYSE:HBMStock Price: $8.44 (-$0.37)P/E Ratio: 36.68Market Cap: $3.32 billionAverage Trading Volume: 4.76 million sharesDividend Yield: 0.17%<Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $11.17 (32.4% Upside)Hudbay Minerals Inc., a diversified mining company, focuses on the exploration, development, operation, and optimization of properties in North and South America. It produces copper concentrates containing gold, silver, and molybdenum; gold concentrates containing zinc; zinc concentrates; molybdenum concentrates; and silver/gold doré. The company's flagship project is the 100% owned Constancia mine located in the Province of Chumbivilcas in southern Peru. Hudbay Minerals Inc. was founded in 1927 and is based in Toronto, Canada.#7 - Achieve Life SciencesNASDAQ:ACHVStock Price: $3.07 (+$0.22)P/E Ratio: -2.72Market Cap: $105.58 millionAverage Trading Volume: 361,806 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $14.80 (382.1% Upside)Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.#8 - Bioceres Crop SolutionsNASDAQ:BIOXStock Price: $7.01 (-$0.21)P/E Ratio: 350.68Market Cap: $439.60 millionAverage Trading Volume: 239,103 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $12.13 (73.0% Upside)Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, commercializes, and sells inoculants, bio-inductors, and biological and microgranulated fertilizers. It also offers HB4, a drought tolerant seed technology program. The company operates in Argentina, Bolivia, Brazil, Colombia, Estonia, the United States, Paraguay, Russia, South Africa, France, Uruguay, and internationally. Bioceres Crop Solutions Corp. was founded in 2001 and is headquartered in Rosario, Argentina.#9 - Quince TherapeuticsNASDAQ:QNCXStock Price: $1.56 (+$0.08)P/E Ratio: -1.26Market Cap: $68.64 millionAverage Trading Volume: 158,419 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $9.50 (509.0% Upside)Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.#10 - enCore EnergyNASDAQ:EUStock Price: $3.61 (+$0.13)P/E Ratio: -12.89Market Cap: $671.89 millionAverage Trading Volume: 1.56 million sharesConsensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.50 (80.1% Upside)enCore Energy Corp. engages in the acquisition, exploration, and development of uranium resource properties in the United States. It holds a 100% interest in Crownpoint and Hosta Butte uranium project area covers 3,020 acres located in the Grants Uranium Belt, New Mexico. The company also holds interest in the Marquez-Juan Tafoya property comprises 14,582 acres located in McKinley and Sandoval counties of New Mexico; and the Nose Rock project comprising 42 owned unpatented lode mining claims comprising approximately 800 acres located in McKinley County, New Mexico. In addition, it holds interest in the White Canyon District and Utah property package, including the Geitus, Blue Jay, Marcy Look, and Cedar Mountain projects located to the northwest of the White Mesa Mill at Blanding County, Utah. Further, the company holds a 100% interest in Dewey Burdock project comprises approximately 12,613 surface acres and 16,962 net mineral acres located in South Dakota; Gas Hills project consists of approximately 1,280 surface acres and 12,960 net mineral acres of unpatented lode mining claims located in Wyoming; and West Largo project consist of approximately 3,840 acres located in McKinley County, New Mexico. Additionally, it holds a 100% interest in Ambrosia Lake - Treeline property consists of deeded mineral rights totaling 24,555 acres and unpatented mining claims covering approximately 1,700 acres; and Checkerboard mineral rights covering a land position of approximately 300,000 acres located in the Grants Uranium District. The company was formerly known as Wolfpack Gold Corp. and changed its name to enCore Energy Corp. in August 2014. enCore Energy Corp. is headquartered in Corpus Christi, Texas.#11 - Solid BiosciencesNASDAQ:SLDBStock Price: $3.12 (-$0.14)P/E Ratio: -1.03Market Cap: $124.68 millionAverage Trading Volume: 699,884 sharesConsensus Rating: Buy (13 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $15.30 (390.4% Upside)Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.#12 - Aura BiosciencesNASDAQ:AURAStock Price: $7.93P/E Ratio: -4.58Market Cap: $396.10 millionAverage Trading Volume: 133,602 sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $23.00 (190.0% Upside)Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.#13 - Rezolve AINASDAQ:RZLVStock Price: $3.16 (+$0.30)Market Cap: $544.09 millionAverage Trading Volume: 11.27 million sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.40 (102.5% Upside)Rezolve Ai Ltd. operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.#14 - NkartaNASDAQ:NKTXStock Price: $2.48 (+$0.04)P/E Ratio: -1.32Market Cap: $175.01 millionAverage Trading Volume: 1.32 million sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $15.00 (504.8% Upside)Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.#15 - Reviva PharmaceuticalsNASDAQ:RVPHStock Price: $1.94 (-$0.06)P/E Ratio: -1.75Market Cap: $64.87 millionAverage Trading Volume: 2.96 million sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $11.40 (487.6% Upside)Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.#16 - GeoVax LabsNASDAQ:GOVXStock Price: $2.11 (-$0.11)Market Cap: $19.92 millionAverage Trading Volume: 592,363 sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $14.20 (573.0% Upside)GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.#17 - Amprius TechnologiesNYSE:AMPXStock Price: $3.45 (+$0.17)P/E Ratio: -7.66Market Cap: $364.94 millionAverage Trading Volume: 4.88 million sharesConsensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $9.29 (169.3% Upside)Amprius Technologies, Inc. produces and sells ultra-high energy density lithium-ion batteries for mobility applications. The company offers silicon nanowire anode batteries. Its batteries are primarily used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. The company was incorporated in 2008 and is headquartered in Fremont, California.#18 - Mind Medicine (MindMed)NASDAQ:MNMDStock Price: $7.01 (-$0.17)P/E Ratio: -3.10Market Cap: $514.04 millionAverage Trading Volume: 1.55 million sharesConsensus Rating: Buy (12 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $26.75 (281.6% Upside)Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.#19 - ImmunicNASDAQ:IMUXStock Price: $0.98 (+$0.03)P/E Ratio: -0.80Market Cap: $88.60 millionAverage Trading Volume: 1.36 million sharesConsensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $12.67 (1,187.8% Upside)Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.#20 - AlumisNASDAQ:ALMSStock Price: $6.90 (-$0.51)Market Cap: $325.83 millionAverage Trading Volume: 104,814 sharesConsensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $26.83 (288.9% Upside)Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.#21 - HIVE Digital TechnologiesNASDAQ:HIVEStock Price: $3.15 (+$0.03)P/E Ratio: -22.50Market Cap: $454.42 millionAverage Trading Volume: 10.20 million sharesConsensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $7.42 (135.4% Upside)HIVE Digital Technologies Ltd. operates as a cryptocurrency mining company in Canada, Sweden, and Iceland. The company engages in the mining and sale of digital currencies, including Ethereum Classic, Bitcoin, and other coins. It also operates data centers; and offers infrastructure solutions. The company was formerly known as HIVE Blockchain Technologies Ltd. and changed its name to HIVE Digital Technologies Ltd. in July 2023. HIVE Digital Technologies Ltd. was incorporated in 1987 and is headquartered in Vancouver, Canada.#22 - TriSalus Life SciencesNASDAQ:TLSIStock Price: $4.90 (+$0.04)P/E Ratio: -1.97Market Cap: $149.40 millionAverage Trading Volume: 18,665 sharesConsensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $11.79 (140.5% Upside)TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.#23 - Itaú UnibancoNYSE:ITUBStock Price: $5.48 (+$0.07)P/E Ratio: 7.02Market Cap: $53.66 billionAverage Trading Volume: 22.94 million sharesDividend Yield: 0.56%<Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.90 (26.0% Upside)Itaú Unibanco Holding S.A. offers a range of financial products and services to individuals and corporate customers in Brazil and internationally. The company operates through three segments: Retail Banking, Wholesale Banking, and Activities with the Market + Corporation. It offers current account; loans; credit and debit cards; investment and commercial banking services; real estate lending services; financing and investment services; economic, financial and brokerage advisory; and leasing and foreign exchange services. The company also provides property and casualty insurance products covering loss, damage, or liabilities for assets or persons, as well as life insurance products covering death and personal accident. It serves retail customers, account and non-account holders, individuals and legal entities, high income clients, microenterprises, and small companies, as well as middle-market companies and high net worth clients. The company was formerly known as Itaú Unibanco Banco Múltiplo S.A. and changed its name to Itaú Unibanco Holding S.A. in April 2009. The company was incorporated in 1924 and is headquartered in São Paulo, Brazil. Itaú Unibanco Holding S.A. operates as a subsidiary of IUPAR - Itaú Unibanco Participações S.A.#24 - GeneluxNASDAQ:GNLXStock Price: $3.15 (+$0.26)P/E Ratio: -3.32Market Cap: $108.80 millionAverage Trading Volume: 200,685 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $18.25 (479.4% Upside)Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.#25 - Corvus PharmaceuticalsNASDAQ:CRVSStock Price: $5.44 (+$0.22)P/E Ratio: -5.85Market Cap: $349.57 millionAverage Trading Volume: 643,226 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $12.38 (127.5% Upside)Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California. More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Announces Game-Changing News for the AI Industry Super Micro Computer: Turning Risk Into Reward at the Crossroads SAP’s Strong Momentum: A Bullish Setup for Investors BlackRock Breaks Records: Why the Stock Still Has Room to Run Mobileye's High Short Interest Signals Squeeze Potential Rivian: Weathering the Storm, Poised for Growth? Tesla Cybertruck Discounts: What They Mean for the Stock Price Avient Stock: Manufacturing Play With Double-Digit Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.